Patrice Rioux - Jan 1, 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Acting Chief Medical Officer
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
4
Date filed
1/3/2024, 07:33 PM
Previous filing
Jan 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +10K $0.00 10K Jan 1, 2024 Common Stock 10K $0.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock Options vesting commenced on January 1, 2024 as follows: 833 on January 31, 2024 and each subsequent month-end thereafter.